Home › Funds › Avidity Partners Management LP › VIR
Avidity Partners Management LP position in VIR
VIR BIOTECHNOLOGY INC · Health Care
Avidity Partners Management LP reported holding 519,300 shares of VIR (VIR BIOTECHNOLOGY INC) in its Q2 2026 13F filing — a position valued at US$5.3M, representing 0.85% of its reported portfolio and ranking #18 among its reported holdings. Avidity Partners Management LP has disclosed VIR holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Avidity Partners Management LP's VIR position evolved
Avidity Partners Management LP first disclosed a stake in VIR in Q1 2026 at 950,000 shares (US$8.5M). Across 2 filings, Avidity Partners Management LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 519,300 shares valued at US$5.3M — a reduction of -430,700 shares quarter over quarter.. Notable position changes include a 45% trim in Q2 2026 (shares rose 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 950.00K | $8.51M | New |
| Q2 2026 | 519.30K | $5.29M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VIR and 13F data
VIR (VIR BIOTECHNOLOGY INC) is a Health Care company. 49 other funds we track also report a position in VIR — the largest reported positions include ARCH Venture Management, LLC (US$129.4M), SB INVESTMENT ADVISERS (UK) LTD (US$111.6M), GSK plc (US$87.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VIR
- ARCH Venture Management, LLC 12.69M sh · $129.35M · Q2 2026
- SB INVESTMENT ADVISERS (UK) LTD 10.95M sh · $111.56M · Q2 2026
- GSK plc 8.55M sh · $87.13M · Q2 2026
- ADAR1 Capital Management, LLC 2.46M sh · $25.03M · Q2 2026
- Boxer Capital Management, LLC 1.87M sh · $19.01M · Q2 2026
- GordonMD Global Investments LP 1.35M sh · $13.79M · Q2 2026
- Sio Capital Management, LLC 1.08M sh · $10.96M · Q2 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 853.68K sh · $8.70M · Q2 2026
- Saturn V Capital Management LP 770.64K sh · $7.85M · Q2 2026
- Jones Hill Capital LP 659.21K sh · $6.72M · Q2 2026
- Alta Partners Management Company, L.P. 509.92K sh · $5.20M · Q2 2026
More on Avidity Partners Management LP
FAQ
How long has Avidity Partners Management LP held VIR?
Avidity Partners Management LP has disclosed VIR holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Avidity Partners Management LP's current position in VIR?
As of Q2 2026, Avidity Partners Management LP holds 519.30K shares of VIR (VIR BIOTECHNOLOGY INC), valued at $5.29M, representing 0.85% of its reported portfolio and ranking #18.
Has Avidity Partners Management LP been buying or selling VIR?
In the latest 13F filing (Q2 2026), Avidity Partners Management LP reduced its position in VIR.
Which other funds hold VIR?
Other major institutional holders of VIR include ARCH Venture Management, LLC, SB INVESTMENT ADVISERS (UK) LTD, GSK plc, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.